Tau phosphorylation in brain slices: Pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase

Timothy D. Garver, George A. Oyler, Katherine A. Harris, Rathnagiri Polavarapu, Zahi Damuni, R. A W Lehman, Melvin L. Billingsley

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Tau is a neuron-specific, microtubule-associated protein that forms paired helical filaments (PHFs) of Alzheimer's disease when aberrantly phosphorylated. We have attempted to elucidate the protein kinases and phosphatases that regulate tau phosphorylation. Incubation of rat, human, and rhesus monkey temporal neocortex slices with the phosphatase inhibitor okadaic acid induced epitopes of tau similar to those found in PHFs. Okadaic acid (1-20 μM) induced variant forms of tau at 60-68 kDa, which were recognized by the monoclonal antibodies Alz-50 (in humans only) and 5E2 and two polyclonal antipeptide antisera, OK-1 and OK-2. The phosphorylation- sensitive monoclonal antibody Tau-1 failed to recognize the slowest mobility forms of tau after okadaic acid treatment. FK-520 (1-10 μM), a potent inhibitor of calcineurin activity, was tested in brain slices and found not to alter tau mobility. However, combinations of FK-520 (5 μM) and okadaic acid (100 nM) caused tau mobility shifts similar to those seen after 10 μM okadaic acid treatment; similar results were seen using the calcineurin- selective inhibitor cypermethrin. Treatment of human slices with 10 μM okadaic acid decreased both protein phosphatase 2A and calcineurin activity; FK-520 inhibited only protein phosphatase 2B activity. A proposed tau- directed kinase, 42-kDa mitogen-activated protein kinase (p42(mapk)), was activated by okadaic acid (>100 nM) but not FK-520 (5 μM). Nerve growth factor (100 ng/ml) activated p42(mapk), particularly when used in combination with 100 nM okadaic acid; changes in tau mobility were seen when this kinase was activated. Forskolin (2 μM) antagonized the effects of nerve growth factor on both p42(mapk) activity and tau phosphorylation; forskolin alone had little effect on PHF-like tau formation induced by phosphatase inhibitors. These results outline complex interactions between tau-directed protein kinases and protein phosphatases and suggest potential sites for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)745-756
Number of pages12
JournalMolecular Pharmacology
Volume47
Issue number4
StatePublished - Apr 1995

Fingerprint

Okadaic Acid
Phosphoprotein Phosphatases
Mitogen-Activated Protein Kinases
Phosphorylation
Pharmacology
Brain
Phosphotransferases
Calcineurin
Nerve Growth Factor
Colforsin
Phosphoric Monoester Hydrolases
Protein Phosphatase 2
Microtubule-Associated Proteins
Neocortex
Macaca mulatta
Protein Kinases
Immune Sera
Epitopes
Alzheimer Disease
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Garver, T. D., Oyler, G. A., Harris, K. A., Polavarapu, R., Damuni, Z., Lehman, R. A. W., & Billingsley, M. L. (1995). Tau phosphorylation in brain slices: Pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase. Molecular Pharmacology, 47(4), 745-756.
Garver, Timothy D. ; Oyler, George A. ; Harris, Katherine A. ; Polavarapu, Rathnagiri ; Damuni, Zahi ; Lehman, R. A W ; Billingsley, Melvin L. / Tau phosphorylation in brain slices : Pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase. In: Molecular Pharmacology. 1995 ; Vol. 47, No. 4. pp. 745-756.
@article{aa5504fe07e14f80b261d8a95c042576,
title = "Tau phosphorylation in brain slices: Pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase",
abstract = "Tau is a neuron-specific, microtubule-associated protein that forms paired helical filaments (PHFs) of Alzheimer's disease when aberrantly phosphorylated. We have attempted to elucidate the protein kinases and phosphatases that regulate tau phosphorylation. Incubation of rat, human, and rhesus monkey temporal neocortex slices with the phosphatase inhibitor okadaic acid induced epitopes of tau similar to those found in PHFs. Okadaic acid (1-20 μM) induced variant forms of tau at 60-68 kDa, which were recognized by the monoclonal antibodies Alz-50 (in humans only) and 5E2 and two polyclonal antipeptide antisera, OK-1 and OK-2. The phosphorylation- sensitive monoclonal antibody Tau-1 failed to recognize the slowest mobility forms of tau after okadaic acid treatment. FK-520 (1-10 μM), a potent inhibitor of calcineurin activity, was tested in brain slices and found not to alter tau mobility. However, combinations of FK-520 (5 μM) and okadaic acid (100 nM) caused tau mobility shifts similar to those seen after 10 μM okadaic acid treatment; similar results were seen using the calcineurin- selective inhibitor cypermethrin. Treatment of human slices with 10 μM okadaic acid decreased both protein phosphatase 2A and calcineurin activity; FK-520 inhibited only protein phosphatase 2B activity. A proposed tau- directed kinase, 42-kDa mitogen-activated protein kinase (p42(mapk)), was activated by okadaic acid (>100 nM) but not FK-520 (5 μM). Nerve growth factor (100 ng/ml) activated p42(mapk), particularly when used in combination with 100 nM okadaic acid; changes in tau mobility were seen when this kinase was activated. Forskolin (2 μM) antagonized the effects of nerve growth factor on both p42(mapk) activity and tau phosphorylation; forskolin alone had little effect on PHF-like tau formation induced by phosphatase inhibitors. These results outline complex interactions between tau-directed protein kinases and protein phosphatases and suggest potential sites for therapeutic intervention.",
author = "Garver, {Timothy D.} and Oyler, {George A.} and Harris, {Katherine A.} and Rathnagiri Polavarapu and Zahi Damuni and Lehman, {R. A W} and Billingsley, {Melvin L.}",
year = "1995",
month = "4",
language = "English (US)",
volume = "47",
pages = "745--756",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

Garver, TD, Oyler, GA, Harris, KA, Polavarapu, R, Damuni, Z, Lehman, RAW & Billingsley, ML 1995, 'Tau phosphorylation in brain slices: Pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase', Molecular Pharmacology, vol. 47, no. 4, pp. 745-756.

Tau phosphorylation in brain slices : Pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase. / Garver, Timothy D.; Oyler, George A.; Harris, Katherine A.; Polavarapu, Rathnagiri; Damuni, Zahi; Lehman, R. A W; Billingsley, Melvin L.

In: Molecular Pharmacology, Vol. 47, No. 4, 04.1995, p. 745-756.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tau phosphorylation in brain slices

T2 - Pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase

AU - Garver, Timothy D.

AU - Oyler, George A.

AU - Harris, Katherine A.

AU - Polavarapu, Rathnagiri

AU - Damuni, Zahi

AU - Lehman, R. A W

AU - Billingsley, Melvin L.

PY - 1995/4

Y1 - 1995/4

N2 - Tau is a neuron-specific, microtubule-associated protein that forms paired helical filaments (PHFs) of Alzheimer's disease when aberrantly phosphorylated. We have attempted to elucidate the protein kinases and phosphatases that regulate tau phosphorylation. Incubation of rat, human, and rhesus monkey temporal neocortex slices with the phosphatase inhibitor okadaic acid induced epitopes of tau similar to those found in PHFs. Okadaic acid (1-20 μM) induced variant forms of tau at 60-68 kDa, which were recognized by the monoclonal antibodies Alz-50 (in humans only) and 5E2 and two polyclonal antipeptide antisera, OK-1 and OK-2. The phosphorylation- sensitive monoclonal antibody Tau-1 failed to recognize the slowest mobility forms of tau after okadaic acid treatment. FK-520 (1-10 μM), a potent inhibitor of calcineurin activity, was tested in brain slices and found not to alter tau mobility. However, combinations of FK-520 (5 μM) and okadaic acid (100 nM) caused tau mobility shifts similar to those seen after 10 μM okadaic acid treatment; similar results were seen using the calcineurin- selective inhibitor cypermethrin. Treatment of human slices with 10 μM okadaic acid decreased both protein phosphatase 2A and calcineurin activity; FK-520 inhibited only protein phosphatase 2B activity. A proposed tau- directed kinase, 42-kDa mitogen-activated protein kinase (p42(mapk)), was activated by okadaic acid (>100 nM) but not FK-520 (5 μM). Nerve growth factor (100 ng/ml) activated p42(mapk), particularly when used in combination with 100 nM okadaic acid; changes in tau mobility were seen when this kinase was activated. Forskolin (2 μM) antagonized the effects of nerve growth factor on both p42(mapk) activity and tau phosphorylation; forskolin alone had little effect on PHF-like tau formation induced by phosphatase inhibitors. These results outline complex interactions between tau-directed protein kinases and protein phosphatases and suggest potential sites for therapeutic intervention.

AB - Tau is a neuron-specific, microtubule-associated protein that forms paired helical filaments (PHFs) of Alzheimer's disease when aberrantly phosphorylated. We have attempted to elucidate the protein kinases and phosphatases that regulate tau phosphorylation. Incubation of rat, human, and rhesus monkey temporal neocortex slices with the phosphatase inhibitor okadaic acid induced epitopes of tau similar to those found in PHFs. Okadaic acid (1-20 μM) induced variant forms of tau at 60-68 kDa, which were recognized by the monoclonal antibodies Alz-50 (in humans only) and 5E2 and two polyclonal antipeptide antisera, OK-1 and OK-2. The phosphorylation- sensitive monoclonal antibody Tau-1 failed to recognize the slowest mobility forms of tau after okadaic acid treatment. FK-520 (1-10 μM), a potent inhibitor of calcineurin activity, was tested in brain slices and found not to alter tau mobility. However, combinations of FK-520 (5 μM) and okadaic acid (100 nM) caused tau mobility shifts similar to those seen after 10 μM okadaic acid treatment; similar results were seen using the calcineurin- selective inhibitor cypermethrin. Treatment of human slices with 10 μM okadaic acid decreased both protein phosphatase 2A and calcineurin activity; FK-520 inhibited only protein phosphatase 2B activity. A proposed tau- directed kinase, 42-kDa mitogen-activated protein kinase (p42(mapk)), was activated by okadaic acid (>100 nM) but not FK-520 (5 μM). Nerve growth factor (100 ng/ml) activated p42(mapk), particularly when used in combination with 100 nM okadaic acid; changes in tau mobility were seen when this kinase was activated. Forskolin (2 μM) antagonized the effects of nerve growth factor on both p42(mapk) activity and tau phosphorylation; forskolin alone had little effect on PHF-like tau formation induced by phosphatase inhibitors. These results outline complex interactions between tau-directed protein kinases and protein phosphatases and suggest potential sites for therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=0028913558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028913558&partnerID=8YFLogxK

M3 - Article

C2 - 7723735

VL - 47

SP - 745

EP - 756

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -